Ozempic: Facts and Fiction

• Ozempic, Wegovy, and Mounjaro are all brand names for medications in a class called glucagon-like peptide-1 (GLP-1) receptor agonists. They work by mimicking the natural GLP-1 hormone in your body, which helps regulate blood sugar, slows down gastric emptying, and reduces appetite.

• • Ozempic (semaglutide) is FDA-approved for treating type 2 diabetes and reducing the risk of cardiovascular events in people with type 2 diabetes and established cardiovascular disease. It is also prescribed off-label for weight loss.
  • Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
  • Mounjaro (tirzepatide) is FDA approved for the treatment of type 2 diabetes mellitus. It is also prescribed off-label for weight loss. It is a dual incretin medication that w

Ozempic, Wegovy, and Mounjaro are all administered via weekly subcutaneous injection (under the skin).

Clinical trials have demonstrated the effectiveness of all three medications for weight loss. Wegovy is specifically approved for weight management. Ozempic and Mounjaro are approved for diabetes, but are also used off-label for weight loss. All three medications have demonstrated significant weight loss results in clinical trials. However, like all medications, they can have potential side effects. It’s crucial to discuss the risks and benefits with your doctor to determine if they are right for you. It’s also important to remember that these medications are most effective when combined with lifestyle changes, including a healthy diet and regular exercise.

The most common side effects of Ozempic, Wegovy, and Mounjaro are gastrointestinal-related, such as nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are often mild and temporary, but they can be more severe in some individuals. Other potential side effects include fatigue, headache, and injection site reactions. Mounjaro can also cause hypoglycemia in some patients. Less common but more serious side effects can occur, so it’s important to discuss any concerns with your Atrium provider.

These medications are not suitable for everyone. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. They may also not be appropriate for people with certain other medical conditions, such as pancreatitis or severe gastrointestinal disorders. It’s crucial to disclose your complete medical history to your provider before starting any of these medications. Pregnant or breastfeeding women should also avoid these medications.

Weight loss results vary from person to person. Clinical trials have shown that these medications can lead to significant weight loss, especially when combined with lifestyle modifications such as diet and exercise. For example, in clinical trials, Wegovy reduced weight by an average of 15% to 20%. Ozempic, while primarily a diabetes medication, has also demonstrated weight loss benefits, with trials showing an average weight reduction of 5% to 10%. Mounjaro, as a newer medication, also shows promising results for weight loss, which can be discussed with your doctor. Your doctor can give you a more personalized estimate based on your individual circumstances.

It’s possible to regain some weight if you stop taking Ozempic, Wegovy, or Mounjaro. These medications are most effective when used in conjunction with long-term lifestyle changes, including a healthy diet and regular physical activity. Your doctor can help you develop a plan to maintain your weight loss after stopping the medication. These medications are not a “quick fix” and ongoing lifestyle changes are essential.

Insurance coverage for Ozempic, Wegovy, and Mounjaro varies depending on your insurance plan. Wegovy, being specifically approved for weight loss, may have more limited coverage than Ozempic and Mounjaro, which are approved for diabetes. It’s essential to check with your insurance provider to understand your specific coverage. The blog post also mentions that some plans may require prior authorization.